KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash & Equivalents (2018 - 2025)

Esperion Therapeutics' Cash & Equivalents history spans 8 years, with the latest figure at $167.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 15.95% year-over-year to $167.9 million; the TTM value through Dec 2025 reached $167.9 million, up 15.95%, while the annual FY2025 figure was $167.9 million, 15.95% up from the prior year.
  • Cash & Equivalents reached $167.9 million in Q4 2025 per ESPR's latest filing, up from $92.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $226.6 million in Q1 2024 to a low of $82.2 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $147.7 million, with a median of $144.7 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 76.01% in 2024, then crashed 54.54% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $208.9 million in 2021, then plummeted by 40.27% to $124.8 million in 2022, then plummeted by 34.08% to $82.2 million in 2023, then surged by 76.01% to $144.8 million in 2024, then grew by 15.95% to $167.9 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Cash & Equivalents are $167.9 million (Q4 2025), $92.4 million (Q3 2025), and $86.1 million (Q2 2025).